BACKGROUND: The presence of a graft-versus- @entity5 effect has been well established for various @entity1583 but not for @entity1073 ( @entity1073 ). We report preliminary results suggestive of a graft-versus- @entity706 effect in such @entity1 post allogeneic hematopoietic transplantation. @entity1 AND METHODS: Sixteen @entity1 with the diffuse type of @entity1073 received allogeneic transplantation. Three had blastic features. Fifteen had an HLA-identical and one, a one HLA antigen mismatched sibling donor. Fifteen had stage IV disease. Eleven @entity1 were previously treated, including one who failed prior autologous transplantation. Five @entity1 were newly diagnosed and received transplantation after cytoreduction with three to eight courses of HYPER-CVAD (fractionated @entity786 , @entity632 , @entity1891 , @entity619 ) alternating with high-dose @entity1499 and @entity2592 . RESULTS: Eleven @entity1 received high-dose @entity786 120 mg/kg and @entity348 ( @entity348 ) (12 Gy given in four daily fractions). Three @entity1 were not eligible for @entity348 and received the BEAM regimen. Twelve (85.7%) achieved complete and two (14.3%) partial response. Two additional @entity1 received a nonablative preparative regimen consisting of @entity900 , @entity2592 and @entity3118 . One failed to engraft and later relapsed. The other @entity1 had progressive disease one month post transplant but later achieved complete remission now durable for 14+ months after developing @entity2132 ( @entity2132 ). @entity706 was assessed in seven @entity1 by polymerase chain reaction assay (PCR) for @entity4910 or immunoglobulin gene rearrangement. All had detectable disease at the time of transplant. When tested within four months post transplant, four of these @entity1 attained molecular remission. One of the three molecular non-responders converted to a negative PCR status seven months later and one fluctuates between positive and negative PCR fourteen months post transplant. @entity1349 ( @entity1349 ) and failure-from-progression (FFP) at three years were both 55% (95% confidence interval (95% CI): 28%-83%). For @entity1 with chemosensitive disease, FFP and @entity1349 at one year were both 90% (95% CI: 71%-100%) compared with 44% (95% CI: 1%-88%) (P = 0.04) for those who were refractory to conventional chemotherapy at the time of transplantation. There were six deaths. These were related to @entity2132 (three cases), @entity281 (one case), @entity177 (one case), and graft failure (one case). CONCLUSIONS: This report demonstrates the potential efficacy of allogeneic hematopoietic transplantation for @entity1073 and provides the first evidence suggestive of graft-versus-malignancy in @entity1073 . Data supportive of this concept include 1) achievement of remission concomitant with @entity2132 , 2) the conversion from a positive PCR status early after transplant to negative PCR status over time and 3) that the only relapse was in a @entity1 who failed to engraft.

Allogeneic hematopoietic transplantation for XXXX : molecular remissions and evidence of graft-versus-malignancy.

@entity1 :: ('9606', 'Species') :: ['patient', 'patients', 'PATIENTS'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'Residual lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity4910 :: ('595', 'Gene') :: ['bcl-1'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity177 :: ('MESH:D051437', 'Disease') :: ['multiorgan failure'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-versus-host disease'] @entity348 :: ('MESH:C535338', 'Disease') :: ['TBI', 'total body irradiation'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['MCL', 'mantle-cell lymphoma'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']
@entity1073 :: (MESH:D020522,Disease) :: ['mantle-cell lymphoma']
